1. Home
  2. CUE vs RFL Comparison

CUE vs RFL Comparison

Compare CUE & RFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cue Biopharma Inc.

CUE

Cue Biopharma Inc.

HOLD

Current Price

$0.29

Market Cap

27.1M

Sector

Health Care

ML Signal

HOLD

Logo Rafael Holdings Inc. Class B

RFL

Rafael Holdings Inc. Class B

HOLD

Current Price

$1.49

Market Cap

61.1M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
CUE
RFL
Founded
2014
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Real Estate
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
27.1M
61.1M
IPO Year
2017
2017

Fundamental Metrics

Financial Performance
Metric
CUE
RFL
Price
$0.29
$1.49
Analyst Decision
Strong Buy
Analyst Count
2
0
Target Price
$3.00
N/A
AVG Volume (30 Days)
366.6K
58.8K
Earning Date
01-01-0001
03-30-2026
Dividend Yield
N/A
N/A
EPS Growth
35.14
28.28
EPS
N/A
N/A
Revenue
$9,287,000.00
$917,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$25.00
N/A
P/E Ratio
N/A
N/A
Revenue Growth
69.16
43.96
52 Week Low
$0.23
$1.12
52 Week High
$1.21
$3.19

Technical Indicators

Market Signals
Indicator
CUE
RFL
Relative Strength Index (RSI) 39.68 76.62
Support Level $0.28 $1.41
Resistance Level $0.36 $1.60
Average True Range (ATR) 0.02 0.07
MACD 0.00 0.02
Stochastic Oscillator 25.81 75.61

Price Performance

Historical Comparison
CUE
RFL

About CUE Cue Biopharma Inc.

Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.

About RFL Rafael Holdings Inc. Class B

Rafael Holdings Inc is a biotechnology firm that develops pharmaceuticals and invests in clinical and early-stage companies in pharmaceuticals and medical devices. Trappsol Cyclo is in Phase 3 trials for Niemann-Pick Disease Type C1. The company focuses on completing these trials, seeking regulatory approval, and commercializing the product. It also invests in portfolio companies including Cyclo, LipoMedix, Barer, Rafael Medical Devices, Cornerstone, and Day Three, targeting therapeutics for unmet medical needs. The business operates through three segments: Healthcare, Infusion Technology, and Real Estate. Operations are based in the United States and Israel.

Share on Social Networks: